Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2013
Event: Completion of the sale of the Company's entire shareholding in Oxford Nanopore Technologies Ltd.
Key Financial Metrics
- Sale Proceeds: £56.4 million (approximately $91.1 million).
- Recorded Gain: $55.2 million.
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the divestiture of the Company's investment in Oxford Nanopore. The transaction was initiated with a transfer notice on September 23, 2013, and finalized on November 15, 2013. This resulted in a significant one-time gain of $55.2 million.
Outlook, Commentary, and Risks
Management Commentary: The Company confirmed that its existing commercialization agreement with Oxford Nanopore remains in effect following the sale of the equity stake.
Risks and Contingencies: The filing does not disclose specific new risks or contingencies beyond the standard regulatory disclaimers regarding the non-filing status of the information under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the impact of the $55.2 million gain on the Company's quarterly earnings per share and net income.
- Confirm the terms and duration of the continuing commercialization agreement with Oxford Nanopore.
- Review the Company's cash flow statement to confirm the receipt of the $91.1 million in proceeds.
- Assess whether the divestiture alters the Company's long-term strategic focus on sequencing technologies.